Via practica 1/2012
Prevention of stroke in atrial fibrillation: current state and trends
Given the complexities of warfarin use for stroke prevention in atrial fibrillation (SPAF), availability of novel oral anticoagulants such as dabigatran, rivaroxaban, and apixaban could serve to reduce well – documented treatment gaps in this clinical context, increasing the percentage of atrial fibrillation (AF) patients at risk of stroke who receive appropriate antithrombotic therapy.
Keywords: atrial fibrillation, risk of stroke, antithrombotic therapy, aspirin, warfarin, new oral anticoagulants.
